ArticleInternational journal of obesity (2005)2020
Obesity and the paradox of mortality and heart failure hospitalization in heart failure with preserved ejection fraction.
Article in International journal of obesity (2005), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 42 citations in OpenAlex.
- Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial.European heart journal · 2025Trial
- Association of Body Mass Index and Abdominal Obesity with Incidence of Atrial Fibrillation in Heart Failure with Preserved Ejection Fraction.Current medicinal chemistry · 2025Trial
- Trial
- Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction.European heart journal · 2021Trial
- Obesity Definitions and Hospital Stay in Older Adults with Heart Failure: A Post Hoc Analysis of a Prospective Cohort.Cardiac failure review · 2026Article
- What Is Cardiometabolic HFpEF and How Can We Study it Preclinically?JACC. Basic to translational science · 2025Review
- Treatment options for heart failure in individuals with overweight or obesity: a review.Future cardiology · 2025Review
- THE OBESITY PARADOX IN HEART FAILURE: TIME TO MOVE FORWARD.Transactions of the American Clinical and Climatological Association · 2025Review
- Association between triglyceride glucose-body mass index and long-term adverse outcomes of heart failure patients with coronary heart disease.Cardiovascular diabetology · 2024Article
- Exploring the association between asthma and chronic comorbidities: impact on clinical outcomes.Frontiers in medicine · 2024Review
- Body mass index and survival in people with heart failure.Heart (British Cardiac Society) · 2023Article
- Article
- Relationship between BMI and prognosis of chronic heart failure outpatients in Vietnam: a single-center study.Frontiers in nutrition · 2023Article
- Nutrition Assessment and Dietary Interventions in Heart Failure: JACC Review Topic of the Week.Journal of the American College of Cardiology · 2022Review
- Body Mass Index, Muscle Mass, and All-Cause Mortality in Patients With Acute Heart Failure: The Obesity Paradox Revisited.International journal of heart failure · 2022Article
- Obesity paradox and heart failure.Eating and weight disorders : EWD · 2021Review
- Prevention and Treatment of Heart Failure: We Want to Pump You Up.JACC. Cardiovascular imaging · 2021Article
- Disparate effects of obesity on survival and hospitalizations in heart failure with preserved ejection fraction.International journal of obesity (2005) · 2020Article
- Implications of obesity across the heart failure continuum.Progress in cardiovascular diseasesReview
- Trends and disparities in heart failure and heart failure with obesity mortality among U.S. adults: A 1999-2020 analysis of geographic, gender, and racial variations using CDC WONDER data.Journal of multimorbidity and comorbidityArticle
Corrections and comments
- Commented on by
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLimited data exist on the association of obesity with both hospitalization and mortality in patients with heart failure with preserved ejection fraction (HFpEF), especially in the real-world ambulatory setting. We hypothesized that increasing body-mass index (BMI) in ambulatory heart failure with preserved ejection fraction would have a protective effect on these patients leading to decreased mortality and hospitalizations.
methodsWe studied the relationship between BMI and the time to all-cause mortality, time to heart failure (HF) hospitalization, and time to all-cause hospitalization over a 2-year follow-up in a national cohort of 2501 ambulatory HFpEF patients at 153 Veterans Affairs medical centers.
resultsCompared with normal BMI, overweight (HR 0.72; 95% CI 0.57-0.91), obesity class I (HR 0.59; 95% CI 0.45-0.77), obesity class II (HR 0.56; 95% CI 0.40-0.77), and obesity class III (HR 0.53; 95% CI 0.36-0.77) were associated with improved survival after adjustment for demographics and comorbidities. In contrast, the time to HF hospitalization showed an inverse relationship, with shorter time to HF hospitalization with increasing BMI compared with normal BMI; overweight (adjusted HR 1.30; 95% CI 0.88-1.90), obesity class I (HR 1.57; 95% CI 1.05-2.34), obesity class II (HR 1.79; 95% CI 1.15-2.78), and obesity class III (HR 1.96; 95% CI 1.23-3.12). However, time to first all-cause hospitalization was not significantly different by BMI groups.
conclusionsIn a large, national ambulatory HFpEF cohort, despite the presence of the obesity paradox with respect to survival, increasing BMI was independently associated with an increased risk of HF hospitalization and similar risk of all-cause hospitalization. Future longer-term prospective trials evaluating the safety and efficacy of weight loss on morbidity and mortality, in patients with severe obesity and HFpEF are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.